Physician profile
Rachel Kingree
NPI 1114020336
$16,468.91
in general payments reported to CMS, 2019-2025
45 companies · $1,823 in 2025
The $1,823 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,843 · 2020: $1,976 · 2021: $1,754 · 2022: $1,736 · 2023: $5,727 · 2024: $1,611 · 2025: $1,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,009 · Education: $3,124 · Travel and Lodging: $1,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,008.65 |
| Education | $3,123.56 |
| Travel and Lodging | $1,028.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,085.29 | 2023 | Ion, Da Vinci Surgical System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,983.25 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $1,807.00 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,799.26 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Grifols USA, LLC | $853.91 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $781.06 | 2019-2025 | Dupixent |
| Insmed, INC. | $773.91 | 2019-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $720.70 | 2019-2024 | Uptravi, Opsumit |
| Genzyme Corporation | $511.42 | 2019-2025 | |
| Electromed, INC. | $438.38 | 2019-2025 | Smartvest |
| United Therapeutics Corporation | $332.92 | 2021-2024 | Tyvaso |
| Jazz Pharmaceuticals INC. | $214.30 | 2020-2025 | |
| Mylan Specialty L.P. | $211.62 | 2019-2024 | Yupelri |
| Genentech USA, INC. | $197.95 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $128.90 | 2020-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Kingree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.